Overview of current immunotherapeutic strategies for glioma.

Expression of the galectin-9-Tim-3 pathway in glioma tissues is associated with the clinical manifestations of glioma. Oncol Lett (2016) 0.80

Recent advances and future of immunotherapy for glioblastoma. Expert Opin Biol Ther (2016) 0.77

Simultaneous blockade of interacting CK2 and EGFR pathways by tumor-targeting nanobioconjugates increases therapeutic efficacy against glioblastoma multiforme. J Control Release (2016) 0.76

Immunosuppressive Myeloid Cells' Blockade in the Glioma Microenvironment Enhances the Efficacy of Immune-Stimulatory Gene Therapy. Mol Ther (2017) 0.75

Immature myeloid cells in the tumor microenvironment: Implications for immunotherapy. Clin Immunol (2016) 0.75

Chimeric antigen receptors for treatment of glioblastoma: a practical review of challenges and ways to overcome them. Cancer Gene Ther (2016) 0.75

Convection-enhanced Delivery of Therapeutics for Malignant Gliomas. Neurol Med Chir (Tokyo) (2016) 0.75

Multiple Expressed Endogenous Glioma Epitopes as Novel Vaccines for Gliomas. Clin Cancer Res (2016) 0.75

Targeting Malignant Brain Tumors with Antibodies. Front Immunol (2017) 0.75

Single vs. combination immunotherapeutic strategies for glioma. Expert Opin Biol Ther (2017) 0.75

Dogs are man's best friend: in sickness and in health. Neuro Oncol (2017) 0.75

Improved survival with ipilimumab in patients with metastatic melanoma. N Engl J Med (2010) 67.34

Safety, activity, and immune correlates of anti-PD-1 antibody in cancer. N Engl J Med (2012) 52.99

Safety and activity of anti-PD-L1 antibody in patients with advanced cancer. N Engl J Med (2012) 35.24

The blockade of immune checkpoints in cancer immunotherapy. Nat Rev Cancer (2012) 24.94

Guidelines for the evaluation of immune therapy activity in solid tumors: immune-related response criteria. Clin Cancer Res (2009) 24.11

Tumor-associated B7-H1 promotes T-cell apoptosis: a potential mechanism of immune evasion. Nat Med (2002) 23.42

Engagement of the PD-1 immunoinhibitory receptor by a novel B7 family member leads to negative regulation of lymphocyte activation. J Exp Med (2000) 19.81

Safety and tumor responses with lambrolizumab (anti-PD-1) in melanoma. N Engl J Med (2013) 18.08

Cancer regression in patients after transfer of genetically engineered lymphocytes. Science (2006) 16.96

Nivolumab in previously untreated melanoma without BRAF mutation. N Engl J Med (2014) 10.38

Natural innate and adaptive immunity to cancer. Annu Rev Immunol (2011) 7.09

Immunologic escape after prolonged progression-free survival with epidermal growth factor receptor variant III peptide vaccination in patients with newly diagnosed glioblastoma. J Clin Oncol (2010) 6.30

CBTRUS statistical report: Primary brain and central nervous system tumors diagnosed in the United States in 2006-2010. Neuro Oncol (2013) 6.19

Single-cell RNA-seq highlights intratumoral heterogeneity in primary glioblastoma. Science (2014) 6.09

The causes and consequences of genetic heterogeneity in cancer evolution. Nature (2013) 5.91

Intratumor heterogeneity in human glioblastoma reflects cancer evolutionary dynamics. Proc Natl Acad Sci U S A (2013) 5.68

Antigen presentation by chemically modified splenocytes induces antigen-specific T cell unresponsiveness in vitro and in vivo. J Exp Med (1987) 5.48

Phase III randomized clinical trial comparing tremelimumab with standard-of-care chemotherapy in patients with advanced melanoma. J Clin Oncol (2013) 5.36

Dramatic increase in the numbers of functionally mature dendritic cells in Flt3 ligand-treated mice: multiple dendritic cell subpopulations identified. J Exp Med (1996) 5.32

Management of immune-related adverse events and kinetics of response with ipilimumab. J Clin Oncol (2012) 5.23

CTLA-4-mediated inhibition in regulation of T cell responses: mechanisms and manipulation in tumor immunotherapy. Annu Rev Immunol (2001) 5.17

SHP-1 and SHP-2 associate with immunoreceptor tyrosine-based switch motif of programmed death 1 upon primary human T cell stimulation, but only receptor ligation prevents T cell activation. J Immunol (2004) 4.58

Ipilimumab in combination with paclitaxel and carboplatin as first-line treatment in stage IIIB/IV non-small-cell lung cancer: results from a randomized, double-blind, multicenter phase II study. J Clin Oncol (2012) 4.44

Conditionally replicating herpes simplex virus mutant, G207 for the treatment of malignant glioma: results of a phase I trial. Gene Ther (2000) 4.33

Immune Checkpoint Blockade in Cancer Therapy. J Clin Oncol (2015) 4.25

Immunogenic cell death and DAMPs in cancer therapy. Nat Rev Cancer (2012) 3.76

Immunosurveillance and cancer: epidemiological evidence. Br Med J (1970) 3.68

Tetanus toxoid and CCL3 improve dendritic cell vaccines in mice and glioblastoma patients. Nature (2015) 3.46

Dendritic cell vaccination in glioblastoma patients induces systemic and intracranial T-cell responses modulated by the local central nervous system tumor microenvironment. Clin Cancer Res (2005) 3.35

Ipilimumab (anti-CTLA4 antibody) causes regression of metastatic renal cell cancer associated with enteritis and hypophysitis. J Immunother (2007) 3.32

Stem cell marker CD133 affects clinical outcome in glioma patients. Clin Cancer Res (2008) 3.22

Gene expression profile correlates with T-cell infiltration and relative survival in glioblastoma patients vaccinated with dendritic cell immunotherapy. Clin Cancer Res (2010) 3.05

Increased regulatory T-cell fraction amidst a diminished CD4 compartment explains cellular immune defects in patients with malignant glioma. Cancer Res (2006) 3.02

alpha-type-1 polarized dendritic cells: a novel immunization tool with optimized CTL-inducing activity. Cancer Res (2004) 3.00

Toxicity evaluation of replication-competent herpes simplex virus (ICP 34.5 null mutant 1716) in patients with recurrent malignant glioma. Gene Ther (2000) 2.94

Chemoradiotherapy in malignant glioma: standard of care and future directions. J Clin Oncol (2007) 2.93

Vaccination with tumor lysate-pulsed dendritic cells elicits antigen-specific, cytotoxic T-cells in patients with malignant glioma. Cancer Res (2004) 2.89

Inflammatory signals in dendritic cell activation and the induction of adaptive immunity. Immunol Rev (2009) 2.89

Induction of CD8+ T-cell responses against novel glioma-associated antigen peptides and clinical activity by vaccinations with {alpha}-type 1 polarized dendritic cells and polyinosinic-polycytidylic acid stabilized by lysine and carboxymethylcellulose in patients with recurrent malignant glioma. J Clin Oncol (2010) 2.88

A mutant oncolytic adenovirus targeting the Rb pathway produces anti-glioma effect in vivo. Oncogene (2000) 2.81

Immunological aspects of malignant disease. Lancet (1967) 2.66

The epidemiology of glioma in adults: a "state of the science" review. Neuro Oncol (2014) 2.63

Cancer heterogeneity: implications for targeted therapeutics. Br J Cancer (2013) 2.56

HMGB1 mediates endogenous TLR2 activation and brain tumor regression. PLoS Med (2009) 2.56

Specific recognition and killing of glioblastoma multiforme by interleukin 13-zetakine redirected cytolytic T cells. Cancer Res (2004) 2.54

Adoptive transfer of syngeneic T cells transduced with a chimeric antigen receptor that recognizes murine CD19 can eradicate lymphoma and normal B cells. Blood (2010) 2.52

T-regulatory cells: key players in tumor immune escape and angiogenesis. Cancer Res (2012) 2.43

A herceptin-based chimeric antigen receptor with modified signaling domains leads to enhanced survival of transduced T lymphocytes and antitumor activity. J Immunol (2009) 2.43

Ipilimumab alone or in combination with radiotherapy in metastatic castration-resistant prostate cancer: results from an open-label, multicenter phase I/II study. Ann Oncol (2013) 2.35

NK cells and cancer immunosurveillance. Oncogene (2008) 2.34

Presentation of exogenous antigen with class I major histocompatibility complex molecules. Science (1990) 2.33

A phase I open-label, dose-escalation, multi-institutional trial of injection with an E1B-Attenuated adenovirus, ONYX-015, into the peritumoral region of recurrent malignant gliomas, in the adjuvant setting. Mol Ther (2004) 2.28

Anti-PD-1 blockade and stereotactic radiation produce long-term survival in mice with intracranial gliomas. Int J Radiat Oncol Biol Phys (2013) 2.28

Expression of the B7-related molecule B7-H1 by glioma cells: a potential mechanism of immune paralysis. Cancer Res (2003) 2.27

Phase Ib trial of mutant herpes simplex virus G207 inoculated pre-and post-tumor resection for recurrent GBM. Mol Ther (2008) 2.17

High CD46 receptor density determines preferential killing of tumor cells by oncolytic measles virus. Cancer Res (2004) 2.14

Myeloid-derived suppressor cell accumulation and function in patients with newly diagnosed glioblastoma. Neuro Oncol (2011) 2.13

The EGFRvIII variant in glioblastoma multiforme. J Clin Neurosci (2009) 2.02

Epidermal growth factor receptor VIII peptide vaccination is efficacious against established intracerebral tumors. Clin Cancer Res (2003) 1.92

Systemic CTLA-4 blockade ameliorates glioma-induced changes to the CD4+ T cell compartment without affecting regulatory T-cell function. Clin Cancer Res (2007) 1.86

T cell anergy, exhaustion, senescence, and stemness in the tumor microenvironment. Curr Opin Immunol (2013) 1.79

Recognition of glioma stem cells by genetically modified T cells targeting EGFRvIII and development of adoptive cell therapy for glioma. Hum Gene Ther (2012) 1.75

Combined immunostimulation and conditional cytotoxic gene therapy provide long-term survival in a large glioma model. Cancer Res (2005) 1.74

Durable therapeutic efficacy utilizing combinatorial blockade against IDO, CTLA-4, and PD-L1 in mice with brain tumors. Clin Cancer Res (2014) 1.73

HER2-specific T cells target primary glioblastoma stem cells and induce regression of autologous experimental tumors. Clin Cancer Res (2010) 1.65

Phase I trial of a multi-epitope-pulsed dendritic cell vaccine for patients with newly diagnosed glioblastoma. Cancer Immunol Immunother (2012) 1.54

Growth suppression of intracranial xenografted glioblastomas overexpressing mutant epidermal growth factor receptors by systemic administration of monoclonal antibody (mAb) 806, a novel monoclonal antibody directed to the receptor. Cancer Res (2001) 1.52

Antigen-specific T-cell response from dendritic cell vaccination using cancer stem-like cell-associated antigens. Stem Cells (2009) 1.47

Gene therapy for the treatment of brain tumors using intra-tumoral transduction with the thymidine kinase gene and intravenous ganciclovir. Hum Gene Ther (1993) 1.44

TGF-beta downregulates the activating receptor NKG2D on NK cells and CD8+ T cells in glioma patients. Neuro Oncol (2009) 1.43

A phase II, multicenter trial of rindopepimut (CDX-110) in newly diagnosed glioblastoma: the ACT III study. Neuro Oncol (2015) 1.43

Inflammatory and anti-glioma effects of an adenovirus expressing human soluble Fms-like tyrosine kinase 3 ligand (hsFlt3L): treatment with hsFlt3L inhibits intracranial glioma progression. Mol Ther (2004) 1.42

IL-13Ralpha2 is a glioma-restricted receptor for interleukin-13. Neoplasia (2002) 1.42

Oncolytic virotherapy and immunogenic cancer cell death: sharpening the sword for improved cancer treatment strategies. Mol Ther (2013) 1.41

Essential role of CD91 in re-presentation of gp96-chaperoned peptides. Proc Natl Acad Sci U S A (2004) 1.36

Oncolytic virus therapy for glioblastoma multiforme: concepts and candidates. Cancer J (2012) 1.35

The natural history of EGFR and EGFRvIII in glioblastoma patients. J Transl Med (2005) 1.33

Effective immunotherapy against murine gliomas using type 1 polarizing dendritic cells--significant roles of CXCL10. Cancer Res (2009) 1.32

Immunotherapeutic targeting of shared melanoma-associated antigens in a murine glioma model. Cancer Res (2003) 1.32

Flt3L and TK gene therapy eradicate multifocal glioma in a syngeneic glioblastoma model. Neuro Oncol (2007) 1.31

Intracerebral administration of CpG oligonucleotide for patients with recurrent glioblastoma: a phase II study. Neuro Oncol (2010) 1.30

Autologous T-cell therapy for cytomegalovirus as a consolidative treatment for recurrent glioblastoma. Cancer Res (2014) 1.29

Natural killer cells in human cancer: from biological functions to clinical applications. J Biomed Biotechnol (2011) 1.28

Antitumor effect of immunizations with fusions of dendritic and glioma cells in a mouse brain tumor model. J Immunother (2001) 1.28

HER-2, gp100, and MAGE-1 are expressed in human glioblastoma and recognized by cytotoxic T cells. Cancer Res (2004) 1.26

Heat-shock protein peptide complex-96 vaccination for recurrent glioblastoma: a phase II, single-arm trial. Neuro Oncol (2013) 1.25

Interleukin-13 displaying retargeted oncolytic measles virus strains have significant activity against gliomas with improved specificity. Mol Ther (2008) 1.24

The art of gene therapy for glioma: a review of the challenging road to the bedside. J Neurol Neurosurg Psychiatry (2012) 1.24

Neutrophil degranulation and immunosuppression in patients with GBM: restoration of cellular immune function by targeting arginase I. Clin Cancer Res (2011) 1.22

Dendritic cells are essential for priming but inefficient for boosting antitumour immune response in an orthotopic murine glioma model. Cancer Immunol Immunother (2005) 1.21

Phase II clinical trial of Wilms tumor 1 peptide vaccination for patients with recurrent glioblastoma multiforme. J Neurosurg (2008) 1.16

Individual patient-specific immunity against high-grade glioma after vaccination with autologous tumor derived peptides bound to the 96 KD chaperone protein. Clin Cancer Res (2012) 1.15

CTLA-4 and PD-1 Pathway Blockade: Combinations in the Clinic. Front Oncol (2015) 1.15

ONYX-015: clinical data are encouraging. Nat Med (1998) 1.14

Sequential immunotherapy by vaccination with GM-CSF-expressing glioma cells and CTLA-4 blockade effectively treats established murine intracranial tumors. J Immunother (2012) 1.14

NKT cell networks in the regulation of tumor immunity. Front Immunol (2014) 1.13

A multi-institution phase II study of poly-ICLC and radiotherapy with concurrent and adjuvant temozolomide in adults with newly diagnosed glioblastoma. Neuro Oncol (2010) 1.13

Treatment of intracranial gliomas with bone marrow-derived dendritic cells pulsed with tumor antigens. J Neurosurg (1999) 1.12

Beyond a decade of 5% imiquimod topical therapy. J Drugs Dermatol (2009) 1.12

Combined HSV-TK/IL-2 gene therapy in patients with recurrent glioblastoma multiforme: biological and clinical results. Cancer Gene Ther (2005) 1.11